Chronic Hepatitis C
Amantadine does not improve the value of hepatitis C combination therapy
Published in Hepatitis Weekly, July 4th, 2005
"In an attempt to improve the efficacy of antiviral therapy for chronic hepatitis C, a three-drug combination of pegylated interferon alpha-2b, ribavirin, and amantadine has been suggested. Despite the initial enthusiasm, the role of amantadine in the treatment of chronic hepatitis C remains controversial," scientists writing in the journal Digestive Diseases and Sciences report.
"In a multi-center, open-label clinical trial, the potential efficacy and safety of this triple combination regimen were assessed. In this open-label pilot study, two separate patient...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
Source: Hepatitis Weekly (2005-07-04)
More Articles from Hepatitis Weekly
- Adverse Drug Reaction
Patients with interferon-induced Graves disease fare better than others - Diagnostics
IgM anti-hepatitis C virus titers divulge the threat of acute hepatitis - Hepatocellular Carcinoma
Murine liver tumors respond to combined suicide-cytokine gene therapy - Vaccine Development
Immunostimulatory adjuvant may be key to hepatitis C vaccine efficacy - Vaccine Development
Oligonucleotide prototype boosts immunological response to hepatitis B vaccine - Addiction Medicine
MELD scores are superior predictors of alcoholic hepatitis related mortality - More from this issue of Hepatitis Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
